EMA Issues Positive Opinion on Pfizer Inc. (NYSE:PFE)'S Leukemia Drug Bosutinib - KERX, SNY, AZN

Pompano Beach, FL -- (SBWIRE) -- 01/18/2013 -- Pfizer Inc. (NYSE:PFE) announced that the European Medicines Agency (EMA) released a positive outlook regarding the conditional marketing approval of its cancer drug bosutinib in the European Union for the cure of adult patients with particular types of leukemia.

How Should Investors Trade PFE Now? Don’t Miss out a Special Trend Analysis

Pfizer stated that the optimistic view was accepted by the Committee for Medicinal Products for Human Use and relates to chronic stage, quicker phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia formerly treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib are not believed suitable treatment choices.

Conditional authorizations in the EU are decided to medicinal products with an optimistic benefit/risk calculation that address unmet medical requirements and whose availability would result in an important public health benefit.

Pfizer Inc. (NYSE:PFE) shares so far in this session lost -1.34% to $26.47 with the Stock being traded within the range of $26.43 – $26.67. In the past year, it has not traded below $20.75 and was unable to surpass $26.96. The current session’s volume of 21.87 million shares is down from the average daily trading volume of 30.24 million shares.

Why Should Investors Buy PFE After the Recent Fall? Just Go Here and Find Out

Turning to some other stocks in the same industry, Keryx Biopharmaceuticals, Sanofi SA and AstraZeneca plc are in the volume leaders list. Below in this article, we will have a quick look on their Market performance.

So far in the ongoing trade, Keryx Biopharmaceuticals (NASDAQ:KERX) shares are down -2.27% to $2.80 while the stock has traded within the range of $2.78 – $2.87. In the last 52-week period, shares changed hands between $1.28 and $5.19. The current session’s volume of 293,954 shares is lower than their average daily trading volume of 1.27 million shares.

Will KERX Get Buyers Even After The Recent Rally? Find Out Here

Sanofi SA (ADR) (NYSE:SNY) shares in the current session moved down -2.69% reaching at $47.72. The stock traded in a range of $47.71 – $48.35. In the last year the stock has moved within a range of $33.03 – $49.28. The current session’s volume of 252,690 shares is lower from their average daily trading volume of 1.37 million shares.

Has SNY Found The Bottom and Ready To Move Up? Find Out Here

Another rival company, AstraZeneca plc (ADR) (NYSE:AZN) is at a discount of -0.43% to $48.92. In today’s trading so far, the stock price was found in a range of $48.90 and $49.15. In the previous 52 weeks the stock’s price ranged between $39.72 and $49.28. The current session’s volume of 216,045 shares was higher from their average daily trading volume of 1.21 million shares.

Has AZN Found The Bottom And Ready To Gain Momentum? Find Out Here

About TopStockPlays
The TopStockPlays.com expert team is highly experienced in picking the low-priced shares with the biggest profit potential. We uncover the hidden gems in the stock market-shares that can break out for gains of 300%, 400%, even 500% within a few weeks.

Disclaimer
PLEASE NOTE WELL: The TopStockPlays.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. Please do your research or consults your financial adviser before making any Investment decision. TopStockPlays.com or its employees will not be responsible for any loss or losses.